South Rampart Pharma Announces Presentation at Arrowhead’s 16th Annual Pain Therapeutics Summit
To read the article, click the link above.
South Rampart Pharma Issued Composition of Matter Patent for Novel Non-Toxic Treatment for Pain
To read the article, click the link above.
South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant
To read the article, click the link above.
A New Pain Treatment Requires Accurate And Reliable Data, South Rampart Pharma on Featured on Clinical Leader piece.
To read the article, click the link above.
Co-founder & CEO, Dr. Hernan Bazan, speaks with Dr. Moira Gunn in NPR’s Tech Nation Radio about the need for pain relief innovation.
Dr. Hernan Bazan, the Co-Founder & CEO of South Rampart Pharma Featured on Tech Nation Radio Episode 22-36 Bigotry, justice and environmental pollution To read [...]
South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain
South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain To read the article, click the link above.
South Rampart Pharma Announces Appointment of Josh Blacher as Chief Financial Officer
NEW ORLEANS, Aug. 16, 2022 -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of [...]
South Rampart Pharma Hopes to Develop Safer Pain Medications
South Rampart Pharma Hopes to Develop Safer Pain Medications To read the article, click the link above.
South Rampart Pharma on Empowered Patient Podcast with Karen Jagoda and Dr. Hernan Bazan.
Developing a Non-Opioid Small Molecule Pain Medicine To Overcome the Risks of Organ Toxicity and Abuse. To listen to the podcast, click the link above.
South Rampart Pharma Achieves Development Milestone and Advances to Phase II of Active NIH Fast-Track STTR Commercialization Award
$1.9 million NIH fast-track STTR grant fuels next stage of clinical program dedicated to the development of a novel non-opioid approach to pain management Lead [...]
South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)
SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medications Potential to address the significant unmet need for new, safe, effective, and [...]
South Rampart Pharma Invited to Participate in 2021 NIH Innovation Conference & Life Sciences Summit
NOLABA News - Exciting news for local company South Pharma! They've been selected to participate in the 2021 NIH Innovation Conference (NIC – a half-day, virtual [...]
LSU HSCNO Spin-Out Awarded $1.9M in STTR Fast Track Funding
LSU HSCNO Spin-Out Awarded $1.9M in STTR Fast Track Funding
NIH Awards $1.9 million STTR Grant to Fast Track New Class of Non-Opioid Pain Relievers
NIH Awards $1.9 million STTR Grant to Fast Track New Class of Non-Opioid Pain Relievers
NIH STTR Grant To Fast Track New Class Of Pain Reliever Without Addiction Or Toxicity
The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded a $1.9 million Fast-Track Small Business Technology Transfer [...]
Promising New Analgesic Offers Pain Relief Without Liver Toxicity
Promising New Analgesic Offers Pain Relief Without Liver Toxicity
Novel Analgesic for Pain Relief Lacks Liver Toxicity
Novel Analgesic for Pain Relief Lacks Liver Toxicity
Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects
Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects
South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication
NEW ORLEANS, July 10, 2020 – South Rampart Pharma, LLC (“South Rampart” or “the Company”), a company committed to improving the lives of people suffering [...]
South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication
South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication
Research Roundup: COVID-19 Immunity, Stomach Acid Susceptibility and More
Research Roundup: COVID-19 Immunity, Stomach Acid Susceptibility and More
Researchers Developing Safer Version of Acetaminophen
Researchers Developing Safer Version of Acetaminophen
Novel class of non-addictive analgesics demonstrate safety in animals
To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen. Acute and chronic pain management is [...]
Team Synthesizes Safer Nonaddictive Analgesics
Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce [...]
Safer Class of Painkillers Identified
Safer Class of Painkillers Identified
They discover a new class of pain relievers that do not harm the liver or kidneys
They discover a new class of pain relievers that do not harm the liver or kidneys
A new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage
A new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage
LSU Health New Orleans discovers new class of safer analgesics
New Orleans, LA - Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to [...]
LSU Health New Orleans Discovers New Class of Safer Analgesics
LSU Health New Orleans Discovers New Class of Safer Analgesics
New class of safer analgesics discovered
New class of safer analgesics discovered
A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis
European Journal of Medicinal Chemistry Sept 2020
South Rampart Pharma Issued Composition of Matter Patent for Novel Non-Toxic Treatment for Pain
To read the article, click the link above.
A New Pain Treatment Requires Accurate And Reliable Data, South Rampart Pharma on Featured on Clinical Leader piece.
To read the article, click the link above.
Co-founder & CEO, Dr. Hernan Bazan, speaks with Dr. Moira Gunn in NPR’s Tech Nation Radio about the need for pain relief innovation.
Dr. Hernan Bazan, the Co-Founder & CEO of South Rampart Pharma Featured on Tech Nation Radio Episode 22-36 Bigotry, justice and environmental pollution To read [...]
South Rampart Pharma Hopes to Develop Safer Pain Medications
South Rampart Pharma Hopes to Develop Safer Pain Medications To read the article, click the link above.
South Rampart Pharma on Empowered Patient Podcast with Karen Jagoda and Dr. Hernan Bazan.
Developing a Non-Opioid Small Molecule Pain Medicine To Overcome the Risks of Organ Toxicity and Abuse. To listen to the podcast, click the link above.
South Rampart Pharma Invited to Participate in 2021 NIH Innovation Conference & Life Sciences Summit
NOLABA News - Exciting news for local company South Pharma! They've been selected to participate in the 2021 NIH Innovation Conference (NIC – a half-day, virtual [...]
LSU HSCNO Spin-Out Awarded $1.9M in STTR Fast Track Funding
LSU HSCNO Spin-Out Awarded $1.9M in STTR Fast Track Funding
NIH Awards $1.9 million STTR Grant to Fast Track New Class of Non-Opioid Pain Relievers
NIH Awards $1.9 million STTR Grant to Fast Track New Class of Non-Opioid Pain Relievers
Promising New Analgesic Offers Pain Relief Without Liver Toxicity
Promising New Analgesic Offers Pain Relief Without Liver Toxicity
Novel Analgesic for Pain Relief Lacks Liver Toxicity
Novel Analgesic for Pain Relief Lacks Liver Toxicity
Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects
Researchers Find Alternatives for Acetaminophen Without Liver, Kidney Effects
South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication
South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication
Research Roundup: COVID-19 Immunity, Stomach Acid Susceptibility and More
Research Roundup: COVID-19 Immunity, Stomach Acid Susceptibility and More
Researchers Developing Safer Version of Acetaminophen
Researchers Developing Safer Version of Acetaminophen
Novel class of non-addictive analgesics demonstrate safety in animals
To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen. Acute and chronic pain management is [...]
Team Synthesizes Safer Nonaddictive Analgesics
Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to relieve pain and reduce [...]
Safer Class of Painkillers Identified
Safer Class of Painkillers Identified
They discover a new class of pain relievers that do not harm the liver or kidneys
They discover a new class of pain relievers that do not harm the liver or kidneys
A new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage
A new class of pipeline drugs to relieve pain and reduce fever without the danger of addiction or damage
LSU Health New Orleans discovers new class of safer analgesics
New Orleans, LA - Researchers at LSU Health New Orleans Neuroscience Center of Excellence and colleagues have discovered a new class of pipeline drugs to [...]
New class of safer analgesics discovered
New class of safer analgesics discovered
South Rampart Pharma Announces Presentation at Arrowhead’s 16th Annual Pain Therapeutics Summit
To read the article, click the link above.
South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant
To read the article, click the link above.
South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain
South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain To read the article, click the link above.
South Rampart Pharma Announces Appointment of Josh Blacher as Chief Financial Officer
NEW ORLEANS, Aug. 16, 2022 -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of [...]
South Rampart Pharma Achieves Development Milestone and Advances to Phase II of Active NIH Fast-Track STTR Commercialization Award
$1.9 million NIH fast-track STTR grant fuels next stage of clinical program dedicated to the development of a novel non-opioid approach to pain management Lead [...]
South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)
SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medications Potential to address the significant unmet need for new, safe, effective, and [...]
NIH STTR Grant To Fast Track New Class Of Pain Reliever Without Addiction Or Toxicity
The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded a $1.9 million Fast-Track Small Business Technology Transfer [...]
South Rampart Pharma Identifies New Class of Non-Opioid Pain Medicines in European Journal of Medicinal Chemistry Publication
NEW ORLEANS, July 10, 2020 – South Rampart Pharma, LLC (“South Rampart” or “the Company”), a company committed to improving the lives of people suffering [...]
LSU Health New Orleans Discovers New Class of Safer Analgesics
LSU Health New Orleans Discovers New Class of Safer Analgesics
A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis
European Journal of Medicinal Chemistry Sept 2020
